Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2009

Open Access 01-12-2009 | Research

Do neurooncological patients and their significant others agree on quality of life ratings?

Authors: Johannes M Giesinger, Miriam Golser, Astrid Erharter, Georg Kemmler, Gabriele Schauer-Maurer, Guenter Stockhammer, Armin Muigg, Markus Hutterer, Gerhard Rumpold, Bernhard Holzner

Published in: Health and Quality of Life Outcomes | Issue 1/2009

Login to get access

Abstract

Introduction

Patients suffering from brain tumours often experience a wide range of cognitive impairments that impair their ability to report on their quality of life and symptom burden. The use of proxy ratings by significant others may be a promising alternative to gain information for medical decision making or research purposes, if self-ratings are not obtainable. Our study investigated the agreement of quality of life and symptom ratings by the patient him/herself or by a significant other.

Methods

Patients with primary brain tumours were recruited at the neurooncological outpatient unit of Innsbruck Medical University. Quality of life self- and proxy-ratings were collected using the EORTC QLQ-C30 and its brain cancer module, the QLQ-BN20.

Results

Between May 2005 and August 2007, 42 pairs consisting of a patient and his/her significant other were included in the study. Most of the employed quality of life scales showed fairly good agreement between patient- and proxy-ratings (median correlation 0.46). This was especially true for Physical Functioning, Sleeping Disturbances, Appetite Loss, Constipation, Taste Alterations, Visual Disorders, Motor Dysfunction, Communication Deficits, Hair Loss, Itchy Skin, Motor Dysfunction and Hair Loss. Worse rater agreement was found for Social Functioning, Emotional Functioning, Cognitive Functioning, Fatigue, Pain, Dyspnoea and Seizures.

Conclusion

The assessment of quality of life in brain cancer patients through ratings from their significant others seems to be a feasible strategy to gain information about certain aspects of patient's quality of life and symptom burden, if the patient is not able to provide information himself.
Appendix
Available only for authorised users
Literature
1.
go back to reference Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ: Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 2004,22(4):714–24. 10.1200/JCO.2004.06.078CrossRefPubMed Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ: Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 2004,22(4):714–24. 10.1200/JCO.2004.06.078CrossRefPubMed
2.
go back to reference Taenzer P, Bultz BD, Carlson LE, Speca M, DeGagne T, Olson K, Doll R, Rosberger Z: Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients. Psychooncology 2000,9(3):203–13. 10.1002/1099-1611(200005/06)9:3<203::AID-PON453>3.3.CO;2-PCrossRefPubMed Taenzer P, Bultz BD, Carlson LE, Speca M, DeGagne T, Olson K, Doll R, Rosberger Z: Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients. Psychooncology 2000,9(3):203–13. 10.1002/1099-1611(200005/06)9:3<203::AID-PON453>3.3.CO;2-PCrossRefPubMed
3.
go back to reference MacDonald D, Kiebert G, Padros M, Yung A, Olson J: Benefit of temozolamide compared to procarbazine treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. Cancer Invest 2005,23(2):138–144. 10.1081/CNV-200050453PubMed MacDonald D, Kiebert G, Padros M, Yung A, Olson J: Benefit of temozolamide compared to procarbazine treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. Cancer Invest 2005,23(2):138–144. 10.1081/CNV-200050453PubMed
4.
go back to reference Prados M, Schold S, Fine H, Jaeckle K, Hochberg F, Mechtler L, Fetell M, Phuphanich S, Feun L, Janus T, Ford K, Graney W: A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-Oncol 2003,5(2):96–103. 10.1215/15228517-5-2-96PubMed Prados M, Schold S, Fine H, Jaeckle K, Hochberg F, Mechtler L, Fetell M, Phuphanich S, Feun L, Janus T, Ford K, Graney W: A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-Oncol 2003,5(2):96–103. 10.1215/15228517-5-2-96PubMed
5.
go back to reference Hart M, Grant R, Garside R, Rogers G, Somerville M, Stein K: Temozolomide for high grade glioma. Cochrane Database Syst Rev 2008, 4: CD007415.PubMed Hart M, Grant R, Garside R, Rogers G, Somerville M, Stein K: Temozolomide for high grade glioma. Cochrane Database Syst Rev 2008, 4: CD007415.PubMed
6.
go back to reference Sneeuw KC, Aaronson NK, Osoba D, Muller MJ, Hsu MA, Yung WK, Brada M, Newlands ES: The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care 1997,35(5):490–506. 10.1097/00005650-199705000-00006CrossRefPubMed Sneeuw KC, Aaronson NK, Osoba D, Muller MJ, Hsu MA, Yung WK, Brada M, Newlands ES: The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care 1997,35(5):490–506. 10.1097/00005650-199705000-00006CrossRefPubMed
7.
go back to reference Sneeuw KC, Aaronson NK, Sprangers MA, Detmar SB, Wever LD, Schornagel JH: Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients. J Clin Epidemiol 1998,51(7):617–31. 10.1016/S0895-4356(98)00040-7CrossRefPubMed Sneeuw KC, Aaronson NK, Sprangers MA, Detmar SB, Wever LD, Schornagel JH: Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients. J Clin Epidemiol 1998,51(7):617–31. 10.1016/S0895-4356(98)00040-7CrossRefPubMed
8.
go back to reference Bakitas M, Ahles T, Skalla K, Brokaw F, Byock I, Hanscom B, Lyons K, Hegel M: Proxy perspectives regarding end-of-life care for persons with cancer. Cancer 2008,112(8):1854–61. 10.1002/cncr.23381CrossRefPubMed Bakitas M, Ahles T, Skalla K, Brokaw F, Byock I, Hanscom B, Lyons K, Hegel M: Proxy perspectives regarding end-of-life care for persons with cancer. Cancer 2008,112(8):1854–61. 10.1002/cncr.23381CrossRefPubMed
9.
go back to reference Milne DJ, Mulder LL, Beelen HCM, Schofield P, Kempen GIJM, Aranda S: Patients' self-report and family caregivers' perception of quality of life in patients with advanced cancer: how do they compare? Eur J Cancer Care (Engl) 2006,15(2):125–32. 10.1111/j.1365-2354.2005.00639.xCrossRef Milne DJ, Mulder LL, Beelen HCM, Schofield P, Kempen GIJM, Aranda S: Patients' self-report and family caregivers' perception of quality of life in patients with advanced cancer: how do they compare? Eur J Cancer Care (Engl) 2006,15(2):125–32. 10.1111/j.1365-2354.2005.00639.xCrossRef
10.
go back to reference Wilson KA, Dowling AJ, Abdolell M, Tannock IF: Perception of quality of life by patients, partners and treating physicians. Qual Life Res 2000,9(9):1041–52. 10.1023/A:1016647407161CrossRefPubMed Wilson KA, Dowling AJ, Abdolell M, Tannock IF: Perception of quality of life by patients, partners and treating physicians. Qual Life Res 2000,9(9):1041–52. 10.1023/A:1016647407161CrossRefPubMed
11.
go back to reference Pearcy R, Waldron D, O'Boyle C, MacDonagh R: Proxy assessment of quality of life in patients with prostate cancer: how accurate are partners and urologists? Journal of the Royal Society of Medicine 2008,101(3):133–138. 10.1258/jrsm.2008.081002CrossRefPubMed Pearcy R, Waldron D, O'Boyle C, MacDonagh R: Proxy assessment of quality of life in patients with prostate cancer: how accurate are partners and urologists? Journal of the Royal Society of Medicine 2008,101(3):133–138. 10.1258/jrsm.2008.081002CrossRefPubMed
12.
go back to reference Dawson N, Singer M, Lenert L, Patterson M, Sami S, Gonsenhouser I, Lindstrom H, Smyth K, Barber M, Whitehouse P: Health state valuation in mild to moderate cognitive impairment: feasibility of computer-based, direct patient utility assessment. Medical Decision Making 2008,28(2):220–232. 10.1177/0272989X07311750CrossRefPubMed Dawson N, Singer M, Lenert L, Patterson M, Sami S, Gonsenhouser I, Lindstrom H, Smyth K, Barber M, Whitehouse P: Health state valuation in mild to moderate cognitive impairment: feasibility of computer-based, direct patient utility assessment. Medical Decision Making 2008,28(2):220–232. 10.1177/0272989X07311750CrossRefPubMed
13.
go back to reference Varni J, Limbers C, Burwinkle T: Parent proxy-report of their children's health-related quality of life: an analysis of 13,878 parents' reliability and validity across age subgroups using the PedsQLTM 4.0 Generic Core Scales. Health and Quality of Life Outcomes 2007,5(1):2. 10.1186/1477-7525-5-2CrossRefPubMed Varni J, Limbers C, Burwinkle T: Parent proxy-report of their children's health-related quality of life: an analysis of 13,878 parents' reliability and validity across age subgroups using the PedsQLTM 4.0 Generic Core Scales. Health and Quality of Life Outcomes 2007,5(1):2. 10.1186/1477-7525-5-2CrossRefPubMed
14.
go back to reference Holzner B, Zabernigg A, Kemmler G, Baier S, Kopp M, Sperner Unterweger B: Computerized assessment of quality of life in patients undergoing chemotherapy. Qual Life Res 2004,13(9):1523. Holzner B, Zabernigg A, Kemmler G, Baier S, Kopp M, Sperner Unterweger B: Computerized assessment of quality of life in patients undergoing chemotherapy. Qual Life Res 2004,13(9):1523.
15.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993,85(5):365–76. 10.1093/jnci/85.5.365CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993,85(5):365–76. 10.1093/jnci/85.5.365CrossRefPubMed
16.
go back to reference Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E: The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996,5(1):139–50. 10.1007/BF00435979CrossRefPubMed Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E: The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996,5(1):139–50. 10.1007/BF00435979CrossRefPubMed
17.
go back to reference Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998,16(1):139–44.PubMed Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998,16(1):139–44.PubMed
18.
go back to reference King MT: The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996,5(6):555–67. 10.1007/BF00439229CrossRefPubMed King MT: The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996,5(6):555–67. 10.1007/BF00439229CrossRefPubMed
19.
go back to reference Bland J, Altman D: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 8476: 307–310.CrossRef Bland J, Altman D: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 8476: 307–310.CrossRef
20.
go back to reference Erharter A, Giesinger J, Kemmler G, Schauer-Maurer G, Stockhammer G, Muigg A, Rumpold G, Sperner-Unterweger B, Holzner B: Implementation of computer-based quality of life monitoring in brain tumor outpatients in routine clinical practice. J Pain and Symptom Management, in press. Erharter A, Giesinger J, Kemmler G, Schauer-Maurer G, Stockhammer G, Muigg A, Rumpold G, Sperner-Unterweger B, Holzner B: Implementation of computer-based quality of life monitoring in brain tumor outpatients in routine clinical practice. J Pain and Symptom Management, in press.
21.
go back to reference Brown P, Decker P, Rummans T, Clark M, Frost M, Ballman K, Arusell R, Buckner J: A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: comparison of patient and caregiver ratings of quality of life. Am J Clin Oncol 2008,31(2):163–168. 10.1097/COC.0b013e318149f1d3CrossRefPubMed Brown P, Decker P, Rummans T, Clark M, Frost M, Ballman K, Arusell R, Buckner J: A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: comparison of patient and caregiver ratings of quality of life. Am J Clin Oncol 2008,31(2):163–168. 10.1097/COC.0b013e318149f1d3CrossRefPubMed
22.
go back to reference Weitzner M, Meyers C, Gelke C, Byrne K, Cella D, Levin V: The functional assessment of cancer therapy (FACT) scale: Development of a brain subscale and the revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995, 75: 1151–1161. 10.1002/1097-0142(19950301)75:5<1151::AID-CNCR2820750515>3.0.CO;2-QCrossRefPubMed Weitzner M, Meyers C, Gelke C, Byrne K, Cella D, Levin V: The functional assessment of cancer therapy (FACT) scale: Development of a brain subscale and the revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995, 75: 1151–1161. 10.1002/1097-0142(19950301)75:5<1151::AID-CNCR2820750515>3.0.CO;2-QCrossRefPubMed
23.
go back to reference Gundy C, Aaronson N: The influence of proxy perspective on patient-proxy agreement in the evaluation of health-related quality of life: an empirical study. Medical Care 2008,46(2):209–216. 10.1097/MLR.0b013e318158af13CrossRefPubMed Gundy C, Aaronson N: The influence of proxy perspective on patient-proxy agreement in the evaluation of health-related quality of life: an empirical study. Medical Care 2008,46(2):209–216. 10.1097/MLR.0b013e318158af13CrossRefPubMed
Metadata
Title
Do neurooncological patients and their significant others agree on quality of life ratings?
Authors
Johannes M Giesinger
Miriam Golser
Astrid Erharter
Georg Kemmler
Gabriele Schauer-Maurer
Guenter Stockhammer
Armin Muigg
Markus Hutterer
Gerhard Rumpold
Bernhard Holzner
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2009
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-7-87

Other articles of this Issue 1/2009

Health and Quality of Life Outcomes 1/2009 Go to the issue